The European drug delivery technology market was worth $39.9 billion in the year 2012. The market is segmented on the basis of route of administration into nine categories - oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. Over the years, European drug delivery technology have grown phenomenally from plain drug reformulation and release technologies, to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.
Patent expiries of certain blockbuster drugs, growing demand for self-administration and home healthcare devices, rising incidence of chronic diseases such as cardiovascular diseases, diabetes and cancer and growing focus on pediatric and geriatric patients are accelerating the growth of this market. However, drug failures and recalls and technical barriers are estimated to hamper the growth of this market. Over the years, European drug delivery technology have grown phenomenally from plain drug reformulation and release technologies to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.
The growing number of elderly persons is a large consumer of home care drug delivery devices. Expanding applications of drug delivery into niche therapeutic areas, strategic collaborations and self-administration and home care drug delivery devices represent vast opportunities for key players in this market. According to a 2012 report published by the World Economic Forum (WEF), the total geriatric population of Switzerland (aged 60 years and older) was 23% of the total population. This number is expected to increase to 32% by 2030 and to 37% by 2050. An increase in the number of geriatric patients and rise in demand for convenient drug delivery options pose major opportunities for the development of innovative and easy-to-use systems.
The geographies covered in this study are Germany, France, United Kingdom, Spain, Italy, Russia and Rest of Europe (RoE). Germany is the largest market for drug delivery, followed by France and the U.K. However, these countries are expected to grow at a slower pace than Russia and RoE, primarily due to a certain amount of saturation in the market. The latter markets are poised to register maximum growth over the next five years, owing to the expansion of these economies, increase in disposable income, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases.
Scope of the Report
This research report categorizes the European drug delivery technology market into oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the markets is comprehensively analyzed at a granular level by geography (Germany, France, United Kingdom, Spain, Italy, Russia and Rest of Europe) to provide in-depth information on the European scenario of this market.
European drug delivery market, by technologies
Oral
Controlled Release
Orodispersible Tablets (ODT) and Taste Masking
Others
Pulmonary
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers
Transdermal
Passive
Reservoir System
Matrix System
Active
Iontophoresis
Microporation
Others
Injectable
Conventional Injection Devices
Fillable Syringes
Prefilled Syringes
Self-injection Devices
Needle-free Injecto